Objectives: Long-acting nanoformulated antiretroviral therapy (nanoART) with improved pharmacokinetics, biodistribution and limited systemic toxicities will likely improve drug adherence and access to viral reservoirs.
Introduction
Drug regimen adherence and long-term systemic toxicities are notable risk factors for safety and efficacy of lifelong antiretroviral therapy (ART) [1] . The establishment of ART depots would circumvent this risk by requiring less-frequent drug administrations [2] . Others and we have developed manufacturing techniques to package antiretroviral drugs into long-acting nanoformulations for sustained drug release [3] [4] [5] . Although prior clinical studies support the idea that viral suppression could be achieved with a simplified regimen of the protease inhibitors atazanavir (ATV) and ritonavir (RTV) [6, 7] , none have created long-acting antiretroviral formulations nor correlated immune outcomes with drug distribution to tissue viral reservoirs. Surprisingly, no previous studies correlated end organ or HIV-affected disease outcomes with ART. Thus, we chose to formulate ATV and RTV in order to facilitate drug delivery to maintain viral suppression. Both are safe, well tolerated and efficacious in suppressing viral replication. Therefore, we prepared ATV and RTV ART nanoformulations (nanoART) using an excipient (poloxamer 188; P188). These were prepared by homogenization procedures developed in our laboratories and approved by the Food and Drug Administration [8] . Drug encapsulation through such methods results in high ART load per volume ratios with optimal shapes and sizes enabling rapid uptake and sustained drug release [3, 5, 9, 10] .
ART efficacy and toxicity measures can readily be performed in HIV-infected NOD/scid-IL-2Rg c null (NSG) mice transplanted with human hematopoietic CD34 þ stem cells (HSC) (hu-NSG mice). This new generation of mice, developed in other and our laboratories, permits an extended engraftment of a human immune system and enables a unique platform for testing long-acting ART [11] [12] [13] . Due to longer graft stability and extended end-point evaluations, the model represents a noted advance for HIV-1 therapeutic testing paradigms [14, 15] .
NanoART efficacy was assessed in HIV-1-infected hu-NSG mice injected subcutaneously (s.c.) at weekly dosing intervals. Treatments led to robust tissue drug depots within the reticuloendothelial system and ART concentrations in blood at therapeutic levels. We also demonstrated nanoART maintenance of synaptodendritic morphology, a key pathologic substrate for neurocognitive impairment. Systemic toxicities were limited. Modest changes in serum albumin and blood urea nitrogen (BUN) were observed, but only secondary to comorbid infection and not to nanoART. All together, the consistently robust pharmacodynamic changes in immune restoration and antiretroviral responses strongly support the potential of nanoART for human use.
Materials and methods
Mice NSG mice (The Jackson Laboratories, Bar Harbor, Maine, USA; stock number 005557) were obtained from the established breeding colony and housed under pathogen-free conditions in accordance with ethical guidelines for care of laboratory animals at the National Institutes of Health and the University of Nebraska Medical Center.
Nanoformulated antiretroviral therapy manufacture and in-vitro uptake/release characterization Free-base RTV was purchased from Shengda Pharmaceutical Co., Zhejiang, China. ATV-sulfate was procured from Gyma Laboratories of America Inc. (Westbury, New York, USA). Nanoformulations using the excipient poloxamer-188 (P188; Sigma-Aldrich, St Louis, Missouri, USA) and free base drug were prepared by high-pressure homogenization as described [8, 9] . Drug content was determined by reverse-phase high-performance liquid chromatography (RP-HPLC) [10] and by ultraperformance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) using a Waters ACQUITY UPLC (Waters, Milford, Massachusetts, USA) coupled with an Applied Biosystems 4000 Q TRAP quadruple linear ion trap hybrid mass spectrometer (Applied Biosystems/MDS Sciex, Foster City, California, USA) [16] . Lyophilized particles were resuspended in saline prior to animal injections. For scanning electron microscopy (SEM), 10 ml of nanosuspension were diluted in 1.5 ml of 0.2 mm filtered distilled water and prepared for morphologic examination using a Hitachi S4700 Field-Emission Scanning Electron Microscope (Hitachi High Technologies America Inc., Schaumburg, Illinois, USA) ( Fig. 1a ). In-vitro uptake and release of ATV and RTV was determined in human monocyte-derived macrophages (MDMs) [5] . Human monocytes obtained by elutriation were cultured for 7 days in the presence of macrophage colony-stimulating factor, a generous gift from Pfizer Pharmaceuticals (Cambridge, Massachusetts, USA). MDMs and culture media were collected from cells treated with 100 mmol/l nanoART and extracted using methanol for determination of drug level ( Fig. 1b ) as previously described [10] .
Drug biodistribution assessments
Ten-week-old NSG mice were administered nanoART s.c. at six weekly doses of 250 mg/kg of ATV and RTV (total n ¼ 45, five mice per week), corresponding to a human dose of 20.3 mg/kg based on an interspecies scaling factor of 12.3 [14] . Five mice were sacrificed 3 weeks after drug cessation. The drug concentrations found in sera of NSG mice corresponded to a human dose of 20.3 mg/kg based on an interspecies scaling factor of 12.3 [14] . Animals were sacrificed after each weekly injection and 3 weeks following the last dose for determination of drug levels in serum, liver and spleen.
Generation, selection, infection and treatment of humanized mice CD34 þ HSC were obtained from fetal liver (University of Washington, Laboratory of Developmental Biology supported by NIH Award Number 5R24HD000836) or human cord blood (Department of Gynecology and Obstetrics, UNMC) using a magnetic bead CD34 þ selection kit (Miltenyi Biotec Inc., Auburn, California, USA). Animals were transplanted as previously described [13] . Human pan-CD45, CD3, CD4, CD8, CD14 and CD19 markers were assayed as a six-color combination (BD Pharmingen, San Diego, California, USA) using a fluorescence-activated cell sorting (FACS) Diva (BD Immunocytometry Systems, Mountain View, California, USA) system. The percentages of CD4 þ and CD8 þ cells were obtained from the gate set for human CD3 þ cells. Animals were infected with HIV-1 ADA intraperitoneally at a dose of 10 4 TCID 50 per mouse. The levels of viral RNA copies per ml in plasma were monitored by automated COBAS Amplicor System v1.5 (Roche Molecular Diagnostics, Basel, Switzerland) as described [17] . NanoART was injected in HIV-1-infected and uninfected (control) animals of the same age (n ¼ 5). NanoART was discontinued after six injections and animals were evaluated for an additional 3 weeks. At the study termination, spleen, thymus, lymph nodes, liver, lungs, kidney and brain tissues were collected for cell and viral tests [17] .
Serum biochemistry and tissue histopathology
Serum chemistry profiles were achieved using a VetScan comprehensive diagnostic profile disc interfaced with a VetScan VS-2 instrument (Abaxis Inc., Union City, California, USA). For immunohistochemical analysis, tissues were fixed with 4% paraformaldehyde and embedded in paraffin. Five-micron thick sections were immunostained for CD45LCA (Dako, Carpinteria, California, USA; 1 : 200), human leukocyte antigen-DR (HLA-DR) (clone CR3/43; 1 : 100) and HIV-1 p24 (1 : 10) [13, 18] . Images were obtained with a Nuance EX camera fixed to a Nikon Eclipse E800 using Nuance software (Cambridge Research & Instrumentation, Woburn, Massachusetts, USA). Groups of five mice were sacrificed weekly and 3 weeks after drug cessation. Drug levels were quantified in sera, liver and spleen prior to nanoART injections (red arrow head). In sera, drug was detected from week 1, and in liver and spleen, drug was detected from week 2 as shown in (d). Data are expressed as medians at the 25th and 75th percentiles for n ¼ 5. ART, antiretroviral therapy; ATV, atazanavir; NSG, NOD/scidIL-2Rg c null ; nanoART, nanoformulated antiretroviral therapy; RP-HPLC, reverse-phase highperformance liquid chromatography; RTV, ritonavir; LATV, liver ATV; LRTV, liver RTV; SATV, spleen ATV; SRTV, spleen RTV; UPLC-MS/MS, ultraperformance liquid chromatography tandem mass spectrometry.
Immunofluorescence labeling, multispectral imaging and image analyses Slide specimens (5 mm thick) of paraffin-embedded mouse brains were selected. Brain sections were treated with different paired combinations of primary mouse monoclonal antibodies to 200 and 68 kDa neurofilaments (clone 2F11; 1 : 200; Dako) and synaptophysin (SYN) (1 : 1000; Novus Biologicals, Littleton, Colorado, USA) and rabbit polyclonal antibodies to MAP2 and glial fibrillary acidic protein (GFAP). Primary antibodies were labeled with secondary antimouse and antirabbit antibodies conjugated to the fluorescent probes Alexa Fluor 488 and Alexa Fluor 594, and nuclei were labeled with 4 0 ,6-diamidino-2-phenylindole (DAPI). Slides were coverslipped with ProLong Gold antifade reagent (Invitrogen, Carlsbad, California, USA), allowed to dry for 24 h at room temperature and then stored at À208C for future use. Images were captured at wavelengths encompassing the emission spectra of the probes, with Â20 and Â40 objectives. The fluorescence emission of each probe and autofluorescence of the tissue samples were analyzed and quantitated by multispectral imaging/ image analysis as described [17] .
Statistical analysis
Statistics were summarized using medians and means. The values of cell surface markers CD45, CD4, CD8, CD14 and CD3 were averaged from all the mice. Statistical comparisons were assessed between two groups using a Mann-Whitney U-test and Statistical Package for the Social Sciences. Differences were considered significant at P < 0.05.
Results
Nanoformulated antiretroviral manufacture, characterization and biodistribution ATV and RTV nanoformulations were characterized by morphology and physical properties. In SEM ATV nanoformulations appeared as long slender rods, whereas RTV formulations appeared as rectangular particles (Fig. 1a ). In-vitro uptake of ATVand RTV nanoformulations by human MDMs reached 8.1 AE 0.4 (AESEM) and 16.2 AE 0.5 mg/10 6 cells, respectively. Drug release peaked at day 1 and was sustained until day 10 for RTV. For ATV, the peak drug release was on day 5 and reduced to levels of approximately 2 mg/ml on days 10-15 ( Fig. 1b ). Uptake and long-term release of nanoformulated drugs suggested that macrophages provide therapeutically useful reservoirs of drug and could serve as nanoparticle depots for longterm release.
To assess nanoART biodistribution, nanoformulations of ATV and RTV at 1 : 1 ratios were administered to NSG mice at weekly intervals for 6 weeks. These experiments were performed prior to evaluation of antiretroviral responses to ensure that the correct drug concentrations and dosing intervals were used. The timing of the drug injections is shown by red arrows (Fig. 1c and d) . The ratios of ATV and RTV employed were based on previously optimized data sets [10] . ATV serum levels reached a peak median concentration of 186 ng/ml by week 6 (Fig. 1c ), a level above the minimum effective plasma concentration of 150 ng/ml [19] . Peak RTV serum levels of 213 ng/ml were achieved by week 5. NanoART cessation for 3 weeks led to a drop in serum drug levels to 45-80 ng/ml (week 8). Liver and spleen drug levels, however, were relatively constant from 1000 to over 10 000 ng/ml for both drugs (Fig. 1d ).
In HIV-1-infected humanized mice, after 2 weekly nanoART s.c. injections, mean ATVand RTV levels were 552 and 233 ng/ml in serum, 2407 and 2370 ng/g of tissue in liver (Table 1) , 3065 and 798 ng/g in spleen and 237 and 191 ng/g in lungs, respectively. After 3 weeks of drug interruption in HIV-1-infected mice, liver drug median ATV and RTV concentrations were 1089 ng/g (364-5663) and 376 ng/g (144-515) of tissue weight, respectively ( Table 1 ). Median serum concentrations were 227 ng/ml (128-237) for ATV and 40 ng/g (32-95) for RTV. Notably, there was a significant reduction in RTV compared with ATV serum concentrations in 9-weekold compared with 10-week-old NSG mice, thereby reflecting age-dependent metabolism of protease inhibitors [20] . Control (uninfected) humanized mice of the same age and sex (females) treated with nanoART for 6 weeks followed by 3 weeks of drug interruption showed ATV and RTV levels in sera and liver at a median of 367 and 54 ng/ml and 1816 and 690 ng/g of tissue, respectively (data not shown). Significant differences in serum ATV and RTV concentrations were observed in human cell reconstituted mice as compared with mice that were not reconstituted (P ¼ 0.008; Mann-Whitney U-test).
Antiretroviral responses in nanoformulated antiretroviral therapy treated humanized mice
Hu-NSG mice were infected with HIV-1 ADA at 22 weeks of age ( Fig. 2a ). All mice selected for studies (n ¼ 18) retained circulating human CD45 þ , CD4 þ , CD8 þ T cells, CD19 þ B cells and CD14 þ monocytes and had stable human lymphoid grafts. This was demonstrated by FACS testing of peripheral blood leukocytes, splenocytes and bone marrow cells (supplemental digital content Table 1 , http://links.lww.com/QAD/A243). The FACS gating strategy for human-specific hematopoietic cells in peripheral blood of hu-NSG mice is shown in Fig. 2b . Antiviral activity was assessed following weekly 250 mg/kg nanoART injections administered to chronically HIV-infected hu-NSG mice on which treatment was begun at 8 weeks postinfection (Fig. 2a) . In all ARTnaive virus-infected animals, viral infection was sustained with a median viral load of 1.63 Â 10 5 copies/ml with one exception, where it was detected at 4 weeks after infection (3040 copies/ml) and remained below the detection limit (2500 copies/ml taking into consideration the limited mouse sample volumes available) for study evaluation. To assess nanoARTefficacy, chronically HIV-1-infected hu-NSG mice were divided into untreated (control, n ¼ 6) and treated (nanoART) groups (n ¼ 7). Two HIV mice were sacrificed 1 week after 2 weekly nanoART injections. Animals were evaluated for levels of CD45 (Table 1) , total CD3, CD4 and CD8 cell counts and viral load in blood at 8 weeks after infection (Fig. 2b) . FACS analysis of the peripheral blood after 6 weekly nanoART injections (each injection is illustrated by a red arrow) showed a significant protection of human CD3 þ CD4 þ T cells in treated versus control mice (Fig. 2c ). After four nanoART injections, viral load was reduced by 100-1000-fold and was at or below 2500 copies/ml, the limit of assay detection for analyzed samples (Fig. 2d ). After six injections, therapy ended and animals were evaluated after an additional 3 weeks of therapeutic cessation. Virus rebound was observed in four of five animals (Fig. 2d , nanoART injection times are shown by red arrows). The highest viral loads were in animals with the lowest plasma ATV concentrations in serum (Table 1) . NanoART also prevented HIV-1 infection-induced increases in CD45 þ and CD8 þ cell numbers in bone marrow, spleen and blood (supplemental digital content Table 1 , http://links.lww.com/QAD/ A243).
Histopathological and immunohistochemical changes in infected and/or nanoART-treated animals are shown in Fig. 3 . Lymph node sizes were reduced by up to 50% in HIV-1-infected mice compared with infected and nanoART-treated mice (Fig. 3a) . Interestingly, the medullar regions of the lymph nodes in reconstituted animals were occupied by immature human B cells (Fig. 3a) shown by IgM staining. By 3 weeks after nanoART cessation, the lymphoid organs have an increased expression of HIV-1 p24 þ cells (Fig. 3b ). Equivalent numbers of human cells were in the liver and lung in both groups as shown by HLA-DR staining with readily identified HIV-1 p24 þ cells in untreated animals (Fig. 3c ). Three treated animals with the lowest viral load (217, 1930 and <2500 copies/ml) retained HIV-1 p24 þ infected cells in the lymph nodes ( Fig. 3d) .
Drug toxicity profiles for nanoformulated antiretroviral therapy in HIV-infected mice Reduction in animal weight was observed after the first nanoART injection regardless of infection with a median loss of 5.6% (15.5 AE 0.1%, n ¼ 12). All HIV-infected mice Mice were sacrificed 7 days after second nanoART injection for drug and VL tests; all other mice were sacrificed 3 weeks after six (weekly) nanoART treatments. Mice 1177 (initial VL 296 000) and 1174 (78 500 RNA copies/ml) serum samples were tested at a lower dilution such that values obtained were lower than the detection limit. 'þNanoART' at 1 and 3 weeks refer to the time of the last drug injection. b Comparison of drug concentrations between uninfected and HIV-1-infected mice.
with or without treatment did not experience significant differences in weight (8 AE 3 and 7 AE 3%, respectively). The site of the drug injection showed visible drug depots under the skin without erythema or tissue injury. However, accumulation of mouse and human macrophages were readily observed around places of nanosuspension injections as shown by Iba-1 staining (supplemental digital content Fig. 1 , http://links.lww.com/QAD/A243). Serum chemistry profiles for treated and control animals evaluated at the end of the study showed reduced serum albumin in infected control animals, but not in the treated group, and elevated BUN levels (supplemental digital content Table 2 , http://links.lww.com/QAD/A243). The changes in BUN reflect comorbid infections in some of the uninfected animals, not toxicity.
Nanoformulated antiretroviral therapy protection of HIV-1-induced neural injury
To determine changes in brain architecture, neuronal and glial antigens were analyzed by multispectral fluorescence microscopy of replicate brain regions sampled at study termination. Cortical neurons of HIV-infected animals showed decreased expression of microtubule associated protein 2 (MAP2 þ ) dendrites, whereas animals sacrificed 1 week after two nanoART injections showed significant (P ¼ 0.048) increase in expression of MAP2 þ dendrites with normal morphology (Fig. 4a) . After the 3-week nanoART interruption, MAP2 expression was diminished; neuronal architecture was irregular with wavy contours similar to untreated infected mice.
SYN showed diffuse punctate staining in cortical areas of controls or animals sacrificed 1 week after nanoART treatment but irregularly shaped in both the infected and treatment interrupted groups (Fig. 4a) . Reduction in neurofilament-positive fibers was observed in the cortex of animals with high viral load (both infected and interrupted treatment group), compared to animals with undetectable viral load after 1 week of two nanoART treatments (Fig. 4b) . Captured images were converted to 12-bit gray-scale images and used for quantification. The intensities of MAP2, SYN, neurofilaments and GFAP expression were quantitated as total area labeled (supplemental digital content Fig. 2a and b, http://links.lww.com/QAD/A243). Animals that were either uninfected or HIV-1-infected and nanoARTtreated showed normal brain morphology compared with HIV-infected mice. Increased neurofilament expression was observed in both the cerebral cortex and whisker barrels in nanoART-treated infected mouse brains as compared with virus-infected controls (Fig. 4b) .
The most significant changes were observed in the MAP2 structure and expression in the cerebral cortex and whisker barrels of mice treated twice with nanoART and sacrificed after 7 days (supplemental digital content Fig. 2a and b, http://links.lww.com/QAD/A243) compared with infected untreated group. We also observed a similar pattern of increase in expression in the quantitation of neurofilament and SYN in the nanoART-treated mice but not as pronounced as MAP2 (data not shown). 
Discussion
Drug-associated viral escape from immune surveillance, ART penetration into viral reservoirs and long-term toxicities are limitations of combination ART [21, 22] . We posit that each of these limitations can be overcome, in whole or in part, through the development of longacting nanoART [23, 24] . We fully understand that enabling this process while requiring multidisciplinary approaches in polymer chemistry, cell biology, nanotoxicology, virology, immunology and animal modeling to successfully establish the therapeutic utility of nanoART in relevant animal model of chronic HIV-1 disease also requires patient acceptance of the principles. To this end, a recent clinical epidemiology study demonstrated significant patient support for the type of injectable long-acting nanoART used in this report compared against conventional drug therapy (S. Swindells, personal communication).
The premise of such a drug delivery system resides in the fact that drugs stored in polymer excipients can be readily taken up and stored for extended time periods in tissue skin and macrophages depots. We have recently shown improved access of nanoART to viral central nervous system reservoirs [25] with only subtle immune activation of macrophages. In recent works performed in our laboratory we showed that 90% of the nanoART seen in liver after s.c. injection of rodents was in Kupffer cells (unpublished data). This permits not only the establishment of a cellular depot of ART but also a means for longterm drug protection against metabolism and reduced Fig. 4 . Nanoformulated antiretroviral therapy improves neuronal, synaptic and astrocyte markers damaged following HIV-1 infection. Immunofluorescence labeling of astrocytes, neurofilaments and synapses in brain regions of hu-NSG mice that were uninfected/untreated, infected/untreated, infected/nanoART-treated, and infected/nanoART-treated and interrupted (CS). Representative images captured with the Nuance multispectral imaging system are presented. Slide-mounted sections (5 mm) of brain with VL ranging from very high [untreated and treatment interrupted (CS) group] to less than level of detection (group sacrificed 1 week after two nanoART injections) were stained for (a) dendritic MAP2 (red), synaptic morphology with SYN (green) and nuclei (4 0 ,6-diamidino-2-phenylindole, DAPI) (blue) and (b) GFAP (red), NF (green) nuclei (DAPI) (blue). Infected and nanoART-treated groups have extended dendritic morphological appearance as compared with infected and treatment cessation group, in which punctate structures were observed. The scale bar corresponds to 100 mm.
systemic toxicities as would occur following oral administrations. Drug compartmentalization inside cells could influence natural immunity against the polymer. The potential of monocyte macrophages to serve as 'Trojan horses' for nanoART delivery also facilitates drug delivery to specific sites of active viral infection and replication resulting in another boost to conventional therapeutic options. In screening studies, NSG mice were reconstituted with human peripheral blood lymphocytes then infected and nanoART-treated. These animals showed improved biodistribution and drug activity. The single oral administration of native drugs 24 h before infection was not effective (data not shown), whereas a single subcutaneous administration of nanoARTat an equal dose of 250 mg/kg significantly reduced levels of infection and drug levels in serum and peripheral tissues sustained for 9 days [26] .
The improved pharmacokinetics of selected nanoformulated protease inhibitors were observed in studies after multiple administrations. ATV serum levels were 114-162 ng/ml. This is coincident with the minimal inhibitory concentration (150 ng/ml) for the virus. At the end of the study, the median values of ATV and RTV levels in the liver were higher than in lung and spleen. A differential pattern of drug concentrations in nanoARTtreated mice can be attributed to age [27] and sex [28] influences on cytochrome P450 activity. The distinct metabolism between mice and humans needs to be considered when extrapolating drug concentrations for clinical use [14] .
NanoART treatment resulted in the protection of human CD4 þ cells in the peripheral compartment and the reduction of viral load. As we reported previously, chronic HIV-1 infection in humanized mice induces changes in neuronal morphology [29] [30] [31] and significant reduction of the expression of synaptic, dendritic and axonal proteins [17] . NanoART treatment initiated 8 weeks after infection and following only two weekly injections was coincident with the restoration of neuronal antigen expression in treated HIV-infected animals. The protection of CD4 þ cells and significant reduction in peripheral viral load can be correlated to the reversal of damaged neuronal dendritic morphology. The damaged neuronal architecture seen in nanoART-treated animals after treatment interruption demonstrated that the observed neuropathologic protection could be reversed and also correlated to increased viral load. Another surprising observation was the presence of 'therapeutic' ATV concentrations in blood during viral rebound. This finding certainly requires future investigations to clarify real ATV bioavailability and development of viral resistance.
NanoART treatment in chronically infected humanized mice failed to effectively suppress viral replication in the lymph nodes as detected by strong HIV-1 p24 expression and suggested the inability of ATV to effectively penetrate lymphoid tissues as described for virus-infected people given native drug [32] . However, treated animals have better preserved thymus structure with reduced numbers of human-activated HLA-DR cells and lower presence of immature IgM (Fig. 3a) and IgG-negative B cells. Humanized mice do provide a platform for testing ART efficacy that mimics human disease. In these studies, nanoART was effective in reducing ongoing HIV-1 replication.
The observed changes of serum albumin levels in infected untreated mice and elevated BUN as compared with the nanoART-treated group can be attributed to age [33] , animal food and water intake and sporadic kidney infection. The relationship between these findings and viral infection is currently under investigation [34] . These data, taken together, demonstrate nanoART efficacy patterns approximate infected ART-treated humans.
Conclusion
Overall, this study demonstrates improved drug carriage and ART release through nanoformulation and gives further support for translation of nanoART to the clinic. Important targets for such developments are protease inhibitors (ATV/RTV), which can be used for maintenance therapy in ART-experienced patients [2, 6, 35] .
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